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ABSTRACT
Objectives: To examine the relation between static
and dynamic blood pressure (BP) measurements and
the evolution of kidney function in older people,
adjusted for the presence of multimorbidity.
Design: Retrospective cohort study during a 10-year
time interval (2002–2012) in three age strata of
patients aged 60 and older.
Setting: Primary care registration network with 97
general practitioners working in 55 practices regularly
submitting collected patient data.
Participants: All patients with at least one BP
measurement in 2002 and at least four serum creatine
measurements after 2002 (n=8636). A modified
Charlson Comorbidity Index (mCCI) at baseline was
registered. Change in systolic and diastolic BP (DBP)
and pulse pressure (PP) from 2002 onwards was
calculated. The relation between kidney function
evolution and baseline BP and change in BP was
examined using linear and logistic regression analysis.
Main outcome measures: The slope of the
estimated glomerular filtration rate (eGFR, MDRD,
Modification of Diet in Renal Disease equation) was
calculated by the ordinal least square method. A rapid
annual decline of kidney function was defined as
≥3 mL/min/1.73 m2/year.
Results: Rapid annual decline of kidney function
occurred in 1130 patients (13.1%). High baseline
systolic BP (SBP) and PP predicted kidney function
decline in participants aged 60–79 years. No correlation
between baseline BP and kidney function decline was
found in participants aged 80 years and older. An
annual decline of ≥1 mm Hg in SBP and PP was a
strong risk factor for a rapid annual kidney function
decline in all age strata, independent of baseline BP and
mCCI. A decline in DBP as also a strong independent
predictor in participants aged 60–79 years.
Conclusions: The present study identified a decline in
BP over time as a strong risk factor for kidney function
decline in all age strata, adjusted for mCCI and baseline
kidney function and BP.
INTRODUCTION
Belgium and other western countries are
facing a grey epidemic. Furthermore, a
‘double grey’ epidemic is expected, given the
proportionally higher increase of persons
aged 80 years and older. In 2012, 17.4% and
5.2% of the total Belgian population was
aged 65 years or older, and 80 years or older,
respectively. By 2050, these percentages will
rise to 24.5% and 9.5%, respectively.1 This
will probably lead to a dramatic increase of
chronic diseases and an increased number of
patients with multiple comorbidities.
The prevalence of chronic kidney disease
(CKD) (estimated glomerular filtration rate
(eGFR) <60 mL/min/1.73 m2) increases
with ageing to approximately 10% at the age
of 65 years and to 60% in persons aged
80 years and older.2–4 CKD and especially
end-stage renal disease (ESRD) is recognised
as an important problem in public health.
First, the cost of dialysis per patient per year
Strengths and limitations of this study
▪ The first study that investigated the relation
between dynamic blood pressure measurements
and kidney function over time in participants
aged 60 years and older.
▪ Large primary care study population representa-
tive of the population of Flanders with a long
follow-up period.
▪ Analyses in various age strata were performed in
order to detect possibly different patterns due to
age.
▪ The presence of multimorbidity was included in
the analyses.
▪ Lack of mortality data, data on renal replacement
therapy, insufficient data on proteinuria/albumin-
uria and no standardised measurements of cre-
atinine and blood pressure.
▪ The results are purely descriptive and were not
adjusted for time-dependent changes in medica-
tion prescription and incident comorbidity.
▪ Weaknesses inherent to a retrospective design
and registry data: possible healthy survivor bias,
no information about missing data and loss to
follow-up.
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is more than €50 000, and >1% of the public health
budget of the Belgian government is used to cover these
costs. Second, CKD increases the risk of cardiovascular
events and mortality. Moreover, many medications
cannot be used or need dose adjustment in patients
with CKD.5 6
Arterial hypertension and cardiovascular disease have
been identified both as a cause and as a consequence of
CKD7–9 and ESRD.4 This has been well studied in the
younger population. However, to date, many clinical
trials and clinical studies have excluded older persons
and especially older persons with multiple chronic con-
ditions.10 Furthermore, studies investigating the associ-
ation between arterial hypertension and the risk of
kidney function decline in older persons are scarce. The
Cardiovascular Health study11 and the Systolic
Hypertension in the Elderly Program (SHEP) study8
identified baseline BP as a risk factor for kidney func-
tion decline in older persons. The Leiden 85
Plus-study12 on the other hand, did not find a relation
between baseline BP and kidney function decline. It
reported a decline in systolic BP (SBP) and diastolic BP
(DBP) between ages 85 and 90 years to be related to an
accelerated decline of creatinine clearance over time. To
date, the relation between the evolution of BP and that
of kidney function over time has not been studied in
persons aged 60 years and older. Moreover, the impact
of concomitant chronic conditions on this relation has
not been examined.
Therefore, the aim of this retrospective cohort study
within the framework of a large Flemish morbidity regis-
try was to study the relation between static and dynamic
BP measurements and the evolution of kidney function
over time in three age strata of participants aged 60 years
and older, adjusted for the presence of multimorbidity.
METHODS
Study design and study population
Data were obtained from Intego, a Belgian general
practice-based morbidity registration network at the
Department of General Practice of the University of
Leuven.13 Intego procedures were approved by the
ethical review board of the Medical School of the
Catholic University of Leuven (N° ML 1723) and by the
Belgian Privacy Commission (no SCSZG/13/079).
Ninety-seven general practitioners (GPs) of 55 practices
evenly spread throughout Flanders, Belgium, collaborate
in the Intego project. GPs applied for inclusion in the
registry. Before acceptance of their data, registration per-
formance was audited using algorithms to compare their
results with those of all other applicants. Only the data
of the practices with optimal registration performance
were included in the database. The Intego GPs prospect-
ively and routinely registered all new diagnoses and new
drug prescriptions, as well as laboratory test results and
patient information, using computer-generated keywords
internally linked to codes.
With specially framed extraction software, new data
were encrypted and collected from the GPs’ personal
computers and entered into a central database.
Registered data were continuously updated and historic-
ally accumulated for each patient. New diagnoses were
classified according to a very detailed thesaurus automat-
ically linked to the International Classification of
Primary Care (ICPC-2) and International Statistical
Classification of Diseases and Related Health Problems
10th Revision (ICD-10). Drugs were classified according
to the WHO’s Anatomical Therapeutic Chemical (ATC)
classification system.
The present study used Intego data of a 10-year time
period from 1 January 2002 to 1 January 2012. First,
patients aged 60 years or older in 2002 with a BP meas-
urement registered in 2002 were selected (n=12 904).
Second, patients with at least four serum creatine mea-
surements after 2002 were withheld (n=8636).
Clinical characteristics
Blood pressure
BP measurements registered by the GP in 2002 (baseline
or static BP) and yearly thereafter were used. For each
year of the study time interval, a single SBP and DBP
value was used in the analyses. The average BP of the
two lowest values of that year’s last three measurements
were used.14 Pulse pressure (PP) was calculated as the
difference between the SBP and the DBP. Categories of
baseline BP measurements were based on previously
reported categories.11
The slope of the SBP, DBP and PP (mm Hg/year) was
calculated for every study participant of whom BP mea-
surements were available for at least 4 years following
2002 (n=7283). The slope, or dynamic BP, was calculated
according to the ordinal least square method. Patients
were divided in categories based on the slope using pre-
defined subgroups of ≤−3, >−3 or ≤−1, >−1 or <1, and
≥1 mm Hg/year for the SBP and ≤−1, >−1 or <1 and
≥1 mm Hg/year for the DBP and the PP.
Kidney function
Kidney function was expressed as the eGFR calculated
with the MDRD (Modification of Diet in Renal Disease)
equation.15 Baseline eGFR was calculated based on the
average serum creatine value of the last two measure-
ments in 2002.
The slope of the eGFR (mL/min/1.73 m2/year) for
every participant was calculated according to the ordinal
least square method using all (range 4–50) available
eGFR values. A rapid annual decline of kidney function
was defined as ≥3 mL/min/1.73 m2/year; this change is
known to be associated with clinically deleterious
outcomes.11
Comorbidity
Medical history at baseline of every study participant was
registered. The Charlson Comorbidity Index (CCI)
includes 19 chronic diseases that are weighted based on
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their association with mortality.16 A modified CCI
(mCCI) at baseline was calculated for every study partici-
pant.17 Connective tissue disease could not be reliably
assessed from the registry and the differentiation
between cancers with or without metastasis, diabetes
with or without end organ failure and mild or moderate
to severe liver disease could not be made. Consequently
all patients with cancers were assigned the same score
(=2), as well as all patients with diabetes (=1) and with
liver disease (=1).
The prescription of cardiovascular medication at base-
line including β-blockers, ACE inhibitors, angiotensin
receptor blockers, calcium antagonists and diuretics was
extracted from the database for every study participant.
Data analysis
Continuous data are presented as the mean and SD.
Categorical data are presented as numbers and frequen-
cies. All further analyses were performed in three age
strata at baseline: 60–69, 70–79 and ≥80 years.
The correlation between baseline BP measurements
and kidney function decline and change in BP and
kidney function decline was first explored by calculating
ORs with the corresponding 95% CIs using bivariate
and multivariable linear regression analysis and adjust-
ing for age, gender, mCCI at baseline, cardiovascular
medication at baseline, time between the first and last
eGFR measurement after 2002 (≥ or <5 years) and base-
line eGFR (and baseline BP measurements for BP
change). Second, the relation between categories of
baseline BP measurements or categories of BP change
and a rapid annual decline of kidney function was exam-
ined with bivariate and multivariable logistic regression
analysis.
In order to avoid co-linearity, the correlation coeffi-
cients between all covariates were calculated. In case of
co-linearity (r-value >0.90), only one of the two covari-
ates was considered in the multivariate model.
Interaction was checked between the slope of the BP
measurement and the baseline BP measurement,
between the slope of the BP measurement and the
mCCI, and between the baseline BP measurement and
the mCCI. If the interaction term was statistically signifi-
cant (p<0.05), it was kept in the model. A goodness-
of-fit test was performed with the ANOVA (analysis of
variance) F test for the linear regression models and the
Hosmer-Lemeshow test for the logistic regression
models and was reported when the model did not fit
the observed data (ANOVA F test p≥0.05 and
Hosmer-Lemeshow test p<0.05).
Statistical analyses were performed using SPSS 22.0
(SPSS Inc., Chicago, Illinois, USA) and GraphPad prism
6 (GraphPad Software, San Diego, California, USA).
RESULTS
In total, 8636 patients from the Intego registry had at
least one BP measurement registered in 2002 and at
least four serum creatine measurements after 2002. The
baseline clinical characteristics of the study population
according to their age at baseline are presented in
table 1. After baseline, rapid annual decline of kidney
function occurred in 1130 patients (13.1%): in 9.4%
(n=387) of patients aged 60–69 years, in 15.1% (n=533)
of patients aged 70–79 years and in 21.5% (n=210) of
patients aged 80 years or older. Figure 1 presents the
prevalence of rapid annual decline of kidney function
according to categories of baseline BP and categories of
change in BP. Prevalence of rapid decline of kidney
function increased with higher baseline SBP and PP (χ2
test, p<0.001), as well as with increased decline in SBP,
DBP and PP (χ2 test, p<0.001).
Correlation between SBP and kidney function decline
Baseline SBP
An inverse linear relation was found between baseline
SBP and kidney function decline in all age strata, also
after adjusting for confounders (table 2). The goodness-
of-fit test was not significant in the oldest age stratum
(ANOVA F test, p=0.23). Categories of higher baseline
SBP predicted rapid decline of kidney function in
patients aged 60–69 years (adjusted OR 1.9 (95% CI 1.2
to 3.1) and adjusted OR 2.4 (95% CI 1.5 to 3.9) for 140–
150 mm Hg and ≥150 mm Hg, respectively) (figure 2).
In patients aged 70–79 years a trend was seen for the
highest category (adjusted OR 1.5 (95% CI 1.0 to 2.4),
p=0.052), and no correlation was found in patients aged
80 years or older (Hosmer-Lemeshow test (≥80 years),
p=0.005).
Change in SBP
Figure 3 presents the prevalence of the change in BP for
the various age strata. A positive and independent linear
relation was found between a change in SBP and a
change in kidney function in the oldest two age strata;
the more SBP decreased, the more the kidney function
decreased in the years after 2002 (table 3). Categories of
decreasing SBP showed an increased risk of rapid kidney
function decline compared with no change in patients
60–69 years (adjusted OR 1.7 (95% CI 1.3 to 2.4) and
adjusted OR 3.1 (95% CI 2.0 to 4.6), respectively), in
patients 70–79 years (adjusted OR 1.7 (95% CI 1.3 to
2.3) and adjusted OR 1.9 (95% CI 1.3 to 2.7), respect-
ively) and in patients aged 80 years and older (adjusted
OR 3.3 (95% CI 1.4 to 8.1) and adjusted OR 9.2 (95%
CI 1.8 to 46), respectively) (figure 4). In the oldest age
stratum the model was also corrected for the interaction
term between change in SBP and baseline mCCI
(adjusted OR 1.2 (95% CI 1.0 to 1.3), p=0.026).
Correlation between DBP and kidney function decline
Baseline DBP
No linear relation was found between baseline DBP and
kidney function decline (table 2). The goodness-of-fit
test for the adjusted model was not significant in the
oldest age stratum (ANOVA F test, p=0.64). A trend of
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predicting rapid decline of kidney function was only
seen in the highest category of baseline DBP in patients
aged 60–69 years (adjusted OR 2.0 (95% CI 0.99 to
4.0)). The Hosmer-Lemeshow test showed the adjusted
model in the oldest patients did not fit the observed
data (p<0.001).
Change in DBP
An independent and positive linear relation was found
between change in DBP and change in kidney function
in all age strata (table 3). A decline in DBP predicted
rapid decline of kidney function in patients aged 60–69
and 70–79 years (adjusted OR 2.2 (95% CI 1.7 to 2.9)
Table 1 Baseline characteristics of the study population (n=8636)
60–69 Years 70–79 Years ≥80 Years
n=4128 n=3530 n=978
Men, n (%) 2011 (48.7) 1505 (42.6) 357 (36.5)
Age, mean±SD (years) 64.7±2.8 74.0±2.8 83.1±3.3
Hypertension, n (%) 1855 (44.9) 1738 (49.2) 451 (46.1)
Systolic blood pressure, mean±SD (mm Hg) 134±14 136±14 135±15
Systolic blood pressure categories, n (%), mm Hg
<120 394 (9.5) 264 (7.5) 70 (7.2)
120–129 1001 (24.2) 779 (22.1) 240 (24.5)
130–139 1232 (29.8) 1033 (29.3) 287 (29.3)
140–149 951 (23.0) 872 (24.7) 236 (24.1)
≥150 550 (13.3) 582 (16.5) 145 (14.8)
Diastolic blood pressure (mm Hg), mean±SD 80±8 78±7 76±7
Diastolic blood pressure categories, n (%), mm Hg
<70 143 (3.5) 185 (5.2) 90 (9.2)
70–79 1183 (28.7) 1248 (35.4) 394 (40.3)
80–89 2240 (54.3) 1795 (50.8) 445 (45.5)
≥90 562 (13.6) 302 (8.6) 49 (5.0)
Pulse pressure, mean±SD (mm Hg) 54±11 57±12 59±13
Pulse pressure, n (%), mm Hg
<50 1295 (31.4) 776 (22.0) 194 (19.8)
50–59 1495 (36.2) 1205 (34.1) 308 (31.5)
60–69 940 (22.8) 972 (27.5) 282 (28.8)
≥70 398 (9.6) 577 (16.3) 194 (19.8)
Baseline eGFR, mean±SD (mL/min/1.73 m2) 68.8±13.8 63.2±14.7 55.4±15.3
Baseline eGFR categories, n (%), mL/min/1.73 m2
≥60 3167 (76.7) 2097 (59.4) 356 (36.4)
45–59 850 (20.6) 1119 (31.7) 377 (38.5)
30–44 97 (2.3) 268 (7.6) 204 (20.9)
<30 14 (0.3) 46 (1.3) 41 (4.2)
Charlson comorbidity index, median (IQR), n (%) 3 (2–4) 4 (3–5) 6 (5–7)
Diabetes 859 (20.8) 800 (22.7) 220 (22.5)
Myocardial infarction 231 (5.6) 237 (6.7) 80 (8.2)
Heart failure 135 (3.3) 313 (8.9) 201 (20.6)
CVA or TIA 318 (7.7) 556 (15.8) 229 (23.4)
Peripheral arterial illness 322 (7.8) 404 (11.4) 118 (12.1)
Chronic pulmonary disease 144 (3.5) 146 (4.1) 36 (3.7)
History of peptic ulcer disease 381 (9.2) 393 (11.1) 108 (11.0)
Dementia 49 (1.2) 213 (6.0) 87 (8.9)
Liver disease 172 (4.2) 123 (3.5) 26 (2.7)
Hemiplegia 40 (1.0) 60 (1.7) 20 (2.0)
History of cancer 523 (12.7) 557 (15.8) 148 (15.1)
Leukemia 19 (0.5) 24 (0.7) 6 (0.6)
Lymphoma 20 (0.5) 27 (0.8) 7 (0.7)
Cardiovascular medication, n (%) 2061 (49.9) 1925 (54.5) 554 (56.6)
β-blockers 1262 (30.6) 1122 (31.8) 247 (25.3)
ACE inhibitors 490 (11.9) 509 (14.4) 150 (15.3)
Angiotensin receptor blocker 362 (8.8) 300 (8.5) 79 (8.1)
Calcium antagonist 463 (11.2) 553 (15.7) 167 (17.1)
Diuretic 905 (21.9) 964 (27.3) 338 (34.6)
CVA, cerebrovascular accident; eGFR, estimated glomerular filtration rate; TIA, transient ischaemic attack.
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and adjusted OR 1.4 (1.1 to 1.9), respectively). In the
oldest age stratum a trend of higher risk in patients with a
decline in DBP was seen (adjusted OR 1.5 (95% CI 0.99
to 2.4), p=0.054 (Hosmer-Lemeshow test, p=0.020)).
Correlation between PP and kidney function decline
Baseline PP
An inverse linear correlation was found between baseline
PP and decline in kidney function in all age strata. Only
in the oldest age stratum was the goodness-of-fit test for
the adjusted model not significant (ANOVA F test,
p=0.29). The highest categories of baseline PP predicted
rapid decline of kidney function in patients aged 60–69
years and aged 70–79 years (adjusted OR 1.5 (95% CI 1.0
to 2.2) and adjusted OR 1.4 (95% CI 1.1 to 2.0).
Change in PP
A change in PP was independently correlated with
change in kidney function in the youngest age group
(table 3). The goodness-of-fit test for the adjusted model
was not significant in the oldest age stratum (ANOVA F
test, p=0.18). Patients in all age strata in the category
≤−1 mm Hg/year change showed a higher risk of rapid
annual decline of kidney function compared with
patients without change in PP (adjusted OR 2.1 (95% CI
1.5 to 2.9), adjusted OR 2.8 (95% CI 1.6 to 4.9) and
adjusted OR 1.7 (95% CI 1.1 to 2.8), respectively). In
patients 70–79 years the model was also corrected for
the interaction term between change in PP and baseline
PP (adjusted OR 1.3 (95% CI 1.1 to 1.5), p=0.009).
DISCUSSION
In this large retrospective population-based cohort study
the relation between static and dynamic BP measurements
and kidney function over time in older participants was
investigated. The present study confirmed previously
found associations between baseline BP measurements
and decline of kidney function, but more importantly
identified a decline in BP over time as a strong risk factor
for kidney function decline in all age strata, independent
of the presence of multimorbidity and baseline BP. In
people aged 60–69 years, high baseline SBP and PP pre-
dicted kidney function decline and a decline in SBP, DBP
and PP in the years after baseline were related to a rapid
annual decline in kidney function. In patients aged 70–79
years a relation between high baseline SBP and PP and
kidney function decline was confirmed, and an association
between a decline in SBP, DBP and PP after baseline and a
decline in kidney function was seen. In the oldest age
stratum, no correlation between baseline BP measure-
ments and kidney function decline was found. A decline
in SBP and PP in the years after baseline, however, pre-
dicted a rapid annual decline in kidney function in this
age group. Moreover, DBP tended to decline.
To date, there is no consensus about which level of BP
causes a higher risk of cardiovascular mortality, morbidity
or kidney function decline in the elderly population. In
the KDOQI/KDIGO guidelines tailored BP control is
advised in older persons for the preservation of the
kidney function.18 This evidence is based on several
studies reporting on arterial hypertension as a risk factor
for the development of CKD, as well as on the evolution
of CKD to ESRD in the global population. The
MDRD-trial19 studied arterial hypertension as a risk
factor for kidney function decline in stage 3 and 4 CKD
in a population aged 18–70 years. They studied the
impact of baseline and follow-up BP during 2.2 years on
the evolution of kidney function in an intervention (anti-
hypertensive) and in a control group. No effect of high
Figure 1 Prevalence of rapid annual decline in kidney function according to different blood pressure measurements.
Vaes B, et al. BMJ Open 2015;5:e007571. doi:10.1136/bmjopen-2015-007571 5
Open Access
group.bmj.com on July 1, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
Table 2 Baseline BP as a predictor of change in eGFR in mL/min/1.73 m2/year (linear regression) (n=8636)
60–69 Years
(n=4128)
70–79 Years
(n=3530)
≥80 Years
(n=978)
β (95% CI) p Value β (95% CI) p Value β (95% CI) p Value
Systolic BP (per 10 mm Hg)
Unadjusted −0.14 (−0.21 to −0.066) <0.001 −0.18 (−0.27 to −0.083) <0.001 −0.26 (−0.47 to −0.043) 0.018
Adjusted* −0.14 (−0.21 to −0.064) <0.001 −0.19 (−0.29 to −0.094) <0.001 −0.27 (−0.49 to −0.055) 0.014
Adjusted† −0.11 (−0.18 to −0.034) 0.004 −0.14 (−0.24 to −0.048) 0.003 −0.24 (−0.46 to −0.024) 0.029
CCI (per point increase) −0.15 (−0.23 to −0.061) 0.001 −0.27 (−0.37 to −0.18) <0.001 0.003 (−0.20 to 0.21) 0.97
CV medication −0.28 (−0.49 to −0.073) 0.008 −0.57 (−0.85 to −0.29) <0.001 −0.49 (−1.1 to 0.17) 0.14
Baseline eGFR (per mL/min/1.73 m2) −0.014 (−0.021 to −0.006) <0.001 −0.027 (−0.036 to −0.017) <0.001 −0.004 (−0.028 to 0.019) 0.73
Diastolic BP (per 10 mm Hg)
Unadjusted −0.077 (−0.21 to 0.059) 0.27 −0.12 (−0.31 to 0.069) 0.21 −0.20 (−0.64 to 0.24) 0.38
Adjusted* −0.090 (−0.23 to 0.045) 0.19 −0.16 (−0.35 to 0.032) 0.10 −0.22 (−0.66 to 0.23) 0.34
Adjusted† −0.069 (−0.21 to 0.068) 0.33 −0.14 (−0.33 to 0.056) 0.17 −0.19 (−0.63 to 0.26) 0.41
CCI (per point increase) −0.15 (−0.24 to −0.066) <0.001 −0.28 (−0.38 to −0.19) <0.001 0.001 (−0.20 to 0.20) 0.99
CV medication −0.33 (−0.53 to −0.12) 0.002 −0.61 (−0.88 to −0.33) <0.001 −0.58 (−1.2 to 0.065) 0.078
Baseline eGFR (per mL/min/1.73 m2) −0.014 (−0.022 to −0.007) <0.001 −0.027 (−0.037 to −0.017) <0.001 −0.004 (−0.028 to 0.020) 0.73
Pulse pressure (per 10 mm Hg)
Unadjusted −0.18 (−0.27 to −0.090) <0.001 −0.20 (−0.31 to −0.089) <0.001 −0.26 (−0.50 to −0.025) 0.031
Adjusted* −0.17 (−0.26 to −0.081) <0.001 −0.20 (−0.32 to −0.092) <0.001 −0.27 (−0.51 to −0.033) 0.026
Adjusted† −0.14 (−0.23 to −0.043) 0.004 −0.15 (−0.26 to −0.037) 0.009 −0.25 (−0.49 to −0.002) 0.048
CCI (per point increase) −0.14 (−0.22 to −0.055) 0.001 −0.27 (−0.36 to −0.18) <0.001 0.006 (−0.20 to 0.21) 0.95
CV medication −0.30 (−0.51 to −0.087) 0.005 −0.59 (−0.86 to −0.31) <0.001 −0.51 (−1.16 to 0.14) 0.12
Baseline eGFR (per mL/min/1.73 m2) −0.014 (−0.022 to −0.006) <0.001 −0.027 (−0.037 to −0.017) <0.001 −0.004 (−0.028 to 0.019) 0.72
*Adjusted for age and gender.
†Adjusted for gender, age, baseline CCI, baseline CV medication, time between the first and last eGFR measurement after 2002 (≥5 years), baseline eGFR.
BP, blood pressure; CCI, Charlson Comorbidity Index; CV, cardiovascular; eGFR, estimated glomerular filtration rate.
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BP on kidney function decline was found except for
severe proteinuria >3 g/day. In a cohort of 332 544 men
aged 35–57 years, Klag et al20 found a 22% higher risk of
ESRD in patients with arterial hypertension stage 4,
defined as a SBP >210 mm Hg or a DBP >120 mm Hg,
compared to that of patients with normal BP. In a large
Japanese cohort, Tozawa et al21 included 98 759 patients
aged 20–98 years. They found higher baseline SBP and
Figure 2 Baseline blood pressure (BP) as a predictor of rapid annual decline in kidney function (≥3 mL/min/1.73 m2/year)
(logistic regression) (n=8636). Adjusted for gender, age, baseline Charlson Comorbidity Index, baseline cardiovascular
medication, time between the first and last estimated glomerular filtration rate (eGFR) measurement after 2002, baseline eGFR.
Figure 3 Prevalence (%) of change in systolic and diastolic blood pressures and pulse pressure in different age strata.
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Table 3 Correlation between change in BP and change in eGFR in mL/min/1.73 m2/year (linear regression) (n=7283)
60–69 Years
(n=3696)
70–79 Years
(n=2933)
≥80 Years
(n=654)
β (95% CI) p Value β (95% CI) p Value β (95% CI) p Value
Systolic BP change (per mm Hg/year)
Unadjusted 0.11 (0.058 to 0.16) <0.001 0.14 (0.080 to 0.19) <0.001 0.17 (0.052 to 0.29) 0.005
Adjusted* 0.10 (0.052 to 0.15) <0.001 0.13 (0.076 to 0.19) <0.001 0.17 (0.048 to 0.29) 0.006
Adjusted† 0.030 (−0.025 to 0.086) 0.28 0.069 (0.006 to 0.13) 0.031 1.2 (0.34 to 2.1) 0.007
Baseline BP pressure (per 10 mm Hg) −0.15 (−0.22 to −0.074) <0.001 −0.14 (−0.23 to −0.042) 0.005 −0.11 (−0.37 to 0.15) 0.42
Baseline CCI (per point increase) −0.21 (−0.28 to −0.13) <0.001 −0.28 (−0.36 to −0.19) <0.001 −0.10 (−0.29 to 0.083) 0.28
Baseline CV medication −0.25 (−0.44 to −0.069) 0.007 −0.50 (−0.73 to −0.26) <0.001 −0.61 (−1.2 to −0.023) 0.042
Baseline eGFR (per mL/min/1.73 m2) −0.015 (−0.021 to −0.008) <0.001 −0.021 (−0.030 to −0.013) <0.001 −0.013 (−0.035 to 0.009) 0.24
Interaction term ‘systolic BP change × baseline
systolic BP’
NS NS NS NS −0.079 (−0.14 to −0.014) 0.018
Diastolic BP change (per mm Hg/year)
Unadjusted 0.16 (0.072 to 0.25) <0.001 0.18 (0.073 to 0.29) 0.001 0.38 (0.15 to 0.62) 0.002
Adjusted* 0.15 (0.064 to 0.24) 0.001 0.18 (0.069 to 0.28) 0.001 0.37 (0.14 to 0.61) 0.002
Adjusted† 0.11 (0.008 to 0.21) 0.034 0.14 (0.019 to 0.25) 0.023 0.42 (0.16 to 0.67) 0.001
Baseline diastolic BP (per 10 mm Hg) −0.082 (−0.22 to 0.054) 0.24 0.57 (0.048 to 1.1) 0.032 0.25 (−0.20 to 0.71) 0.27
Baseline CCI (per point increase) −0.22 (−0.29 to −0.14) <0.001 0.91 (0.029 to 1.8) 0.043 −0.13 (−0.32 to 0.052) 0.16
Baseline CV medication −0.31 (−0.50 to −0.13) 0.001 −0.55 (−0.78 to −0.32) <0.001 −0.66 (−1.2 to −0.080) 0.026
Baseline eGFR (per mL/min/1.73 m2) −0.015 (−0.022 to −0.008) <0.001 −0.021 (−0.030 to −0.013) <0.001 −0.015 (−0.037 to 0.007) 0.18
Interaction term ‘baseline diastolic BP ×
baseline CCI’
NS NS −0.15 (−0.27 to −0.041) 0.008 NS NS
Pulse pressure change (per mm Hg/year)
Unadjusted 0.092 (0.031 to 0.15) 0.003 0.13 (0.062 to 0.20) <0.001 0.11 (−0.038 to 0.25) 0.15
Adjusted* 0.086 (0.025 to 0.15) 0.006 0.12 (0.057 to 0.19) <0.001 0.10 (−0.042 to 0.24) 0.17
Adjusted† 0.17 (0.015 to 0.32) 0.031 0.050 (−0.025 to 0.13) 0.19 0.064 (−0.10 to 0.23) 0.45
Baseline pulse pressure (per 10 mm Hg) −0.19 (−0.28 to −0.094) <0.001 −0.15 (−0.26 to −0.043) 0.006 −0.052 (−0.31 to 0.20) 0.69
Baseline CCI (per point increase) −0.20 (−0.27 to −0.13) <0.001 −0.28 (−0.36 to −0.19) <0.001 −0.13 (−0.31 to 0.059) 0.18
Baseline CV medication −0.27 (−0.46 to −0.091) 0.003 −0.52 (−0.75 to −0.28) <0.001 −0.62 (−1.2 to -0.026) 0.041
Baseline eGFR (per mL/min/1.73 m2) −0.015 (−0.022 to −0.008) <0.001 −0.021 (−0.030 to −0.013) <0.001 −0.014 (−0.036 to 0.008) 0.22
Interaction term ‘pulse pressure change ×
baseline CCI’
−0.052 (−0.096 to −0.009) 0.018 NS NS NS NS
*Adjusted for age and gender.
†Adjusted for gender, age at baseline, baseline CCI, baseline CV medication, time between the first and last eGFR measurement after 2002, baseline eGFR and baseline BP measurements.
BP, blood pressure; CCI, Charlson Comorbidity Index; CV, cardiovascular; eGFR, estimated glomerular filtration rate; NS, not significant.
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DBP showed a significant risk of development of ESRD.
Cumulative incidence for ESRD in patients with severe
arterial hypertension was 1.7% vs 0.2% in patients with a
normal BP. Finally, Van Pottelbergh et al22 studied risk
factors for ESRD in patients aged 50 years and older in
the same Flemish cohort study as the present study did.
Baseline arterial hypertension (BP ≥140/90 mm Hg) was
found to be a significant risk factor for the development
of ESRD (adjusted HR 1.25 (95% CI 1.22 to 1.28)).
Studies investigating the impact of BP on the evolution
of kidney function in older persons are extremely rare.
Some studied the risk of baseline BP for kidney function
decline. Rifkin et al11 found baseline SBP to have the
strongest association with rapid annual kidney function
decline in persons aged 65 years or older, with 14%
increased hazard of rapid decline per 10 mm Hg, inde-
pendent of other BP measurements. The SHEP-trial8
used their placebo-arm to study the relation between
baseline BP and a yearly incident increase of serum cre-
atine (≥0.4 mg/dL). They found higher baseline SBP
increased the relative risk of kidney function decline.
A positive trend was found for DBP, however, without
correction for comorbidity. The relation between base-
line BP and the evolution of SBP, DBP and PP and
kidney function decline in a 5-year time interval has
only been studied in patients aged 85 years and older.12
The Leiden 85+ study reported that elevated baseline
SBP and DBP did not influence the annual decline in
renal function in the oldest individuals. However, DBP
<70 mm Hg and a decline in SBP or DBP was related to
an accelerated decline of creatinine clearance over time.
The present study results are in line with these findings.
The deleterious effect of higher baseline BP measure-
ments on the evolution of the kidney function in
persons up to 80 years was confirmed by the present
study. Furthermore, intervention trials have shown that
BP lowering prevents the need for renal replacement
therapy up to the age of 70, independent of renal func-
tion at baseline.23 The question remains how to explain
the observations of the present study that identified a
decline of ≥1 mm Hg/year SBP, DBP or PP as a pre-
dictor of kidney function decline, not only in the oldest
old, as shown in the Leiden 85+ Study, but also in
persons aged 60–79 years old. A decline in BP may lead
to chronic hypoperfusion of the kidney, causing the
kidney function to deteriorate. The cause of BP decline
remains unclear. Underlying heart failure with lowered
cardiac output could be a reason.24 On the other hand,
BP control which is too strict or the effects of antihyper-
tensive medications such as RAAS system inhibitors,
which influence intra-renal BP and renal perfusion
could be responsible. The analyses were corrected for
baseline morbidities, including the presence of heart
failure and history of myocardial infarction, cardiovascu-
lar medication and baseline BP and kidney function.
However, possible changes in medication intake and
occurrence of new morbidities in the years after baseline
could also be underlying the observed relationship.
Furthermore, the results of the present study should be
interpreted with caution, since they originate from an
Figure 4 Correlation between change in blood pressure (BP) and a rapid annual decline in kidney function (≥3 mL/min/1.73 m2/
year) (logistic regression) (n=7283). Adjusted for gender, age at baseline, baseline measurements (systolic or diastolic BP or
pulse pressure), baseline Charlson Comorbidity Index (CCI), baseline cardiovascular medication, time between the first and last
estimated glomerular filtration rate (eGFR) measurement after 2002, baseline eGFR. µAdjusted for interaction term ‘systolic BP
change × baseline CCI’ (adjusted OR of the interaction term 1.2 (95% CI 1.0 to 1.3). *Adjusted for interaction term ‘pulse
pressure change×baseline pulse pressure’ (adjusted OR of the interaction term 1.3 (95% CI 1.1 to 1.5).
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observational registry-based cohort study. However, they
do provide a realistic reflection of every-day practice.
Future analyses should further clarify the findings of this
study before it could lead to an adaptation or refine-
ment of the current guidelines.
This study is the first that investigated the relation
between dynamic BP measurements and kidney function
over time in participants aged 60 years and older. The
major strengths of this study are its large primary care
study population representative of the population of
Flanders and the long follow-up period.13 Because of
the large number of patients included in the study we
were able to perform the analyses in various age strata in
order to detect possibly different patterns due to age.
This study is also the first that included the presence of
multimorbidity in the analyses.
However, the study is limited in that we had neither
mortality data, nor data on the start of renal replace-
ment therapy. Second, the MDRD equation has several
weaknesses as a proxy for the real kidney function. For
example, loss of muscle mass in older people may falsely
give reduced estimates of renal function. However, this
widely used equation to estimate the eGFR corrects for
age that can act as a proxy for muscle mass. Since we
were interested in the evolution of kidney function in
the same population, a change in equation does not
affect model outcomes. Third, no data related to pro-
teinuria or albuminuria could be used in the analyses,
because they were only available for a limited number of
patients. Using these limited albuminuria and protein-
uria data would have caused substantial selection bias.
Fourth, not all creatinine values were measured by the
same laboratory or by the same creatinine assay due to
the design of the database, which collects data from
practices throughout Flanders. However, all Belgian
laboratories are subject to quality control measures,25
which limited the analytical differences among the
laboratories. Fifth, BP measurements were not standar-
dised, but were reported by the GP as measured with
his/her own BP device. Furthermore, the variability in
BP and creatinine measurements in routine clinical
practice may have affected the study findings.
CONCLUSION
This large retrospective, registry-based cohort study
investigated the relation between static and dynamic BP
measurements and the evolution of kidney function,
independent of the presence of multimorbidity.
Previously found associations between baseline BP mea-
surements and decline of kidney function in older
persons were confirmed, but more importantly a decline
in BP over time was identified as a strong risk factor for
kidney function decline in all patients aged 60 years and
older, independent of the presence of multimorbidity
and baseline BP.
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